BioNotebook: Tonix, XenoPort offerings; Ophthotech royalty financing; UniQure, Achaogen IPOs

At the end of a rocky week for the stock market, including biotechnology stocks, it was not surprising to see shares of Tonix Pharmaceuticals and XenoPort lose some value on 24 January after the companies priced separate stock offerings. The declines brought their stocks in line with their offerings, which were priced below the prior day's market values.